ALB-127158A, formerly known as ALB-127158(a), is a MCH1 antagonist for the treatment of obesity. Preclinical studies demonstrated that the compound produced significant weight loss in rodents. ALB-127158(a) may be a potential treatment for IBD. This example displays how using data from the preclinical studies is possible to build decision points into an early clinical development plan that will allow early assessment of potential efficacy and allow timely go/no go decisions. References: Moore NA, Sargent BJ, Guzzo PR, Surman MD. From preclinical to clinical development: the example of a novel treatment for obesity. Neurobiol Dis. 2014 Jan;647-54. doi: 10.1016/j.nbd.2013.07.009. Epub 2013 Jul 25. Review. PubMed PMID: 23891728.

纯度：≥98%

CAS：1173154-32-9